Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (847)	11/5/2003 9:53:25 PM
From: hmpa	Read Replies (1) \| Respond to of 1005

Make it two: biz.yahoo.com Reuters Drug company NitroMed prices IPO at $11 a share Wednesday November 5, 7:18 pm ET NEW YORK, Nov 5 (Reuters) - Pharmaceutical company NitroMed Inc., which is developing a drug to treat heart failure in black people, priced its initial public offering of 6 million common shares at $11 per share on Wednesday. The Bedford, Massachusetts-based company, which develops nitric oxide-based drugs, hopes to use the proceeds for research and development and working capital. The IPO was handled by Deutsche Bank Securities, J.P. Morgan and Pacific Growth Equities, and the underwriters have an option to buy 900,000 extra shares to cover over-allotments. NitroMed will have 25.4 million shares outstanding when the IPO is completed. It has applied for a Nasdaq listing under the symbol "NTMD" (Nasdaq:NTMD - News). The company focuses on treating ailments marked by a deficiency in nitric oxide, such as cardiovascular and inflammatory diseases. It believes its lead nitric oxide-enhancing drug BiDil will be broadly prescribed for heart failure among mainly black patients. (Additional reporting by David Brinkerhoff)

To: tuck who wrote (847)	7/1/2004 1:11:08 PM
From: Jibacoa	Read Replies (1) \| Respond to of 1005

They keep crawling out the window.<g> INHX was expected to come out at a price of $10 to $14 but the IPO came at $7 and they cut the number of shares offered to 5M. INHX had a loss/share of $2.81 in 2003 and $2.29 in 2002 but on the 1stQ (March) earnings were $0.52 on the black column vs. loss of $0.61 in 2003. (Don't know why.<g>) Have to wait for the JuneQ in which they had a loss of $0.76 last year to see what is going on. For the few weeks since the IPO, the price has held above $7 bigcharts.marketwatch.com And did the insiders buy more stock than the $35M that was offered at the IPO? In some places it shows they recently bought $86M ??? Of course, they bought at less than $7/share.<g> news.moneycentral.msn.com Bernard